NCT03703908

A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome

An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Amgen · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

An Open Label, Intra-Subject Dose Escalation Study of CCX140 B in Subjects with Primary FSGS and Nephrotic Syndrome

Detailed description

An Open Label, Intra-Subject Dose Escalation Study of CCX140 B in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome. The aim of this study is to explore the effect of CCX140-B, a selective antagonist of C-C chemokine receptor type 2, on proteinuria in subjects with FSGS. Study acquired by Amgen and all disclosures were done by previous sponsor ChemoCentryx.

Conditions

• Focal Segmental Glomerulosclerosis

Interventions

Type	Name	Description
DRUG	CCX140-B	Orally administered tablet

Timeline

• Start date: 2018-10-01
• Primary completion: 2020-06-24
• Completion: 2020-06-24
• First posted: 2018-10-12
• Last updated: 2025-03-17
• Results posted: 2024-02-06

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study